Bringing you the Best Analytical Legal News
Shardul Amarchand Mangaldas advised Sapphire Foods India Limited and Samara Capital on Sapphire’s merger with Devyani International Limited, consolidating Yum! Brands’ India franchise under a single listed entity.
Shardul Amarchand Mangaldas advised Pune IT City Metro Rail Limited on awarding the operations and maintenance contract for Pune Metro Line III to global mobility major Keolis S.A.
Shardul Amarchand Mangaldas advised the Book Running Lead Managers on ICICI Prudential AMC’s ₹10,602 crore IPO, one of India’s largest offerings, listed on BSE and NSE in December 2025.
Shardul Amarchand Mangaldas advised Nephrocare Health Services Limited (Nephroplus) on its initial public offering aggregating to approximately US$ 95.99 million, covering Indian law, regulatory compliance, and prospectus and listing support.
Shardul Amarchand Mangaldas advised KCC Buildcon Private Limited on the sale of its annuity road assets forming part of the Delhi—Amritsar—Katra Expressway under NHAI’s Hybrid Annuity Model.
Shardul Amarchand Mangaldas advised Attentive.ai Group on its USD 30.5 million Series B funding round led by Insight Partners to scale its AI-driven SaaS platform.
Shardul Amarchand Mangaldas advised Medi Assist Healthcare Services Limited on its INR 198 crore fundraise through a preferential issue to MIT and 238 Plan Associates LLC.
Shardul Amarchand Mangaldas advised KCC Buildcon Private Limited on the sale of its annuity road assets forming part of the Delhi—Amritsar—Katra Expressway to Build India Infrastructure Fund.
Shardul Amarchand Mangaldas advised Tata Steel Limited on its strategic acquisition of a 50.01% stake in Thriveni Pellets Private Limited, strengthening Tata Steel’s long-term value creation strategy.
SAM advised the CoCs of three Arshiya Group entities in an NCLAT-approved multi-CIRP asset sale ensuring operational continuity and value maximisation.
The deal forms part of Wakefit’s broader pre-IPO fundraising ahead of its proposed public listing. SAM advised on transaction, regulatory and tax aspects.
SAM supported the transaction end-to-end, including structuring, diligence, competition, and regulatory aspects. The deal involved multi-team coordination across M&A, private equity, competition, and regulatory practices.
Shardul Amarchand Mangaldas advised Biocon Limited on its ~USD 1.2 billion integration involving acquisition of minority stakes in Biocon Biologics from multiple investors.
SAM advised Eris Lifesciences on acquiring the remaining 30% stake in Swiss Parenterals, making it a wholly owned subsidiary.
The firm provided comprehensive transactional, structuring, and diligence support, marking AION’s full exit from Planetcast and its subsidiaries.
SAM advised on the primary issuance, investor participation, and transaction structuring, reinforcing the Firm’s strength in high-value growth and venture capital deals in the AgriTech sector.
The deal marks Omega Hospitals’ entry into the Bengaluru oncology market and forms part of its nationwide expansion strategy. The transaction involved a full exit by Cytecare’s founding and major shareholders.
Moot court allows the lawyers of tomorrow to critically engage with real world regulatory issues facing the fintech ecosystem today.
The deal involves the complete purchase of CPP India’s share capital from its UK-based sellers. SAM’s team led the transaction and due diligence, strengthening its portfolio in consumer protection and digital services.
This is the largest public offering by an Indian ed-tech company to date. The deal, executed through SEBI’s confidential filing route, saw strong investor demand with 1.81x overall subscription.